DeconGel™ Honored as National Finalist for the Prestigious Christopher Columbus Homeland Security Award
Cellular Bioengineering Inc. (CBI), a Hawaii-based technology accelerator, announced today that it was honored as one of three National Finalists for the Christopher Columbus Foundation Homeland Security Award for 2009. The presentation was made at a National Awards ceremony in the U.S. Capitol in Washington D.C. This award is the result of a year long national competition to identify the individual citizen or company that is making “a measurable and constructive contribution related to basic and/or advanced research in the area of homeland security which will result in a significant and positive benefit to society.”
The Christopher Columbus Fellowship Foundation is an independent Federal government agency established to "encourage and support research, study and labor designed to produce new discoveries in all fields of endeavor for the benefit of mankind." Governed by a Presidential appointed Board of Trustees, the Foundation seeks to nurture and recognize pioneering individuals and programs which reflect the visionary spirit and pioneering heritage of Christopher Columbus.
CBI was chosen to be a finalist for this prestigious award based on its invention and commercialization of DeconGel™, a product of its CBI Polymers Division. DeconGel™ is a polymeric hydrogel which is the state-of-the-art technology for the effective containment and decontamination of radiological waste and potential nuclear threats as well as chemical and other toxic wastes. Nuclear power plants and government agencies such as the U.S. Department of Energy and the U.S. Department of Defense are early customers and users of DeconGel™. Additional applications of DeconGel™ are being expanded for the decontamination of industrial and military grade hazardous chemicals and biological agents.
Kimberly Owens, the Chair of the Board of Trustees for the Christopher Columbus Foundation, congratulated CBI for its development of DeconGel™. “This hydrogel is a powerful tool in the remediation of radioactive waste and nuclear threats, and future uses are sure to be discovered,” she said. Owens went on to assert that the Board had a very difficult decision to make in choosing between the three National Finalists.
DeconGel™ was funded by the Hawaii Technology Development Venture (HTDV) / Office of Naval Research (ONR). Additional R&D funding was secured through the USAF Force Protection Battlelab, the National Defense Center of Excellence for Research in Ocean Sciences (CEROS) under its contract with the Defense Advanced Research Projects Agency (DARPA), and the Department of Energy.
CBI is a venture accelerator focused on disruptive biomedical and biodefense innovations. Founded in 2003 in Honolulu, Hawaii, CBI works with world-class research institutions to transform novel ideas into commercial products, especially in the area of Chemical, Biological, Radiological, and Nuclear (CBRN) detection and remediation.
“We are extremely honored to be named as a National Finalist for this prestigious award,” said Larry Stack, Chief Operating Officer of CBI Polymers. “Our goal as a company is to accelerate the commercialization of innovative technologies that will have a significant impact upon the security and well being of our nation. This award exemplifies CBI’s motto: Invent. Disrupt. Inspire.”
In 2005, CBI was named a winner of the R&D 100 Award and was nominated for The 2009 National Medal of Technology and Innovation, the highest honor for technological achievement bestowed by the President of the United States on America's leading innovators.
Read Full Article
Hawaii Company Develops, Markets High-Tech Cleaner

With an eye for what he calls “disruptive technologies,” Honolulu entrepreneur Hank Wuh has entered the commercial market for cleaning nuclear and hazardous waste.
His company, Cellular Bioengineering Inc., has created a cleaning gel that made its way from research and development to the commercial market in approximately two years.
“CBI continues to search the world for significant disruptive ideas which it can nurture and grow into mature products that will change the way the world operates,” said Wuh, who founded his company in Moiliili in 2003.
Governor Lingle Names Innovation Award Winners

HONOLULU – Governor Linda Lingle today named three recipients of the Governor’s Innovation Awards for their commitment to creative thinking and new ideas which result in better products, services and processes, while also improving Hawai‘i’s future.
“Through ‘disruptive ideas,’ as one of our award winners refers to innovation, this latest group of innovators is helping us all realize the importance of looking beyond what’s always been done, and striving for how we can do things better,” said Governor Lingle. “As these award winners demonstrate, innovation can be something as simple as using native plants to landscape our roadways, to more leading-edge development of new technologies that can restore people’s sight or generate valuable products from marine algae.”
The recipients of the Governor’s Innovation Award for February 2009 are as follows:
Innovation by an Individual: Hank Wuh
In 2003, Hank Wuh founded Cellular Bioengineering Inc. (CBI), a Hawai‘i-based developer of technologies with biomedical and biodefense applications. CBI searches for what Wuh calls “disruptive ideas” and “disruptive technologies” that will eventually overturn the status quo and change the future. Wuh’s company has the worldwide license for the development of a “bio-integrating polymer corneal” substitute called the EYEGENIX™ Artificial Cornea which aims to return the gift of sight to millions of people. Other products are a paint-and-peel gel that can enhance biohazard cleanup and a nanochip that can track pills to thwart counterfeited drugs. With a company motto of “Invent. Disrupt. Inspire.” Wuh and his team at CBI are ensuring that Hawai‘i remains at the forefront of innovative thinking.
Act 221 Success Stories: Cellular Bioengineering

HVCA Technology Entrepreneur Awardees Named
The Hawaii Venture Capital Association has named its first Technology Entrepreneurs of the Year, in a pau-hana event last night at the Plaza Club.
Winners were named in four categories: Lorenz Sell, president of Blue Lava Technologies Inc. as Young Entrepreneur; Bob King, president of Pacific Biodiesel Inc. as Clean Tech Entrepreneur; Jason Lau, managing member of TalkStory Productions LLC as Digital Media Entrepreneur, and Hank Wuh, chief executive officer of Cellular Bioengineering Inc., as Invention Entrepreneur.....CBI Announces the Commercial Launch of DeconGel™
Honolulu, Hawaii – (October 29th, 2008) CBI Polymers, a division of Cellular Bioengineering Inc. (CBI), announced today the launch of its DeconGel™ 1101 product. DeconGel™ is the most effective radiological decontamination solution available to industries worldwide ranging from nuclear power utilities, decommissioning and decontamination sites, hospital facilities, and research laboratories. The worldwide market is estimated to be $200 million per year.
DeconGel™ effectively decontaminates a broad range of surfaces and contaminants. Its extraordinary binding properties allow it to trap and encapsulate a wide spectrum of radioisotopes on different substrates in a simple, no-preparation process allowing easy and safe disposal without the use of water or cleaning agents.
DeconGel™ has been in beta testing for the past year, and has secured more than 30 customers around the world. Current customers include Ontario Power Generation, Washington Savannah River Company, Sandia National Laboratory, Lawrence Livermore National Laboratory, Colorado State University, and Tripler Army Medical Center.
DeconGel™’s advantages and innovations include:
- Immediate fixation of the contamination
- Safe and user friendly
- Cost effective (significantly reduces staff hours spent performing the decontamination procedure)
- Easy application, removal, and disposal
- Environmental friendly, no waste water and a minimal amount of solid waste generated
“DeconGel™ is an amazing contribution to our industry. We especially like how easy and efficient DeconGel™ is to use,” stated Dan Young, First Line Manager at Ontario Power Generation, “We used the gel to decontaminate a concrete room that was difficult to clean with our current method. The application was very simple. We applied the gel and peeled the next day. It came up from the floor very easily with minimal waste generated and reduced the loose contamination from 5000 cpm (counts per minute) to 0 cpm.”
“Using DeconGel™ resulted in substantial cost savings for our department,” said Tom Johnson, PhD., Assistant Professor in the Department of Environmental and Radiological Health at Colorado State University, “We utilized DeconGel™ to effectively decontaminate volatized tritiated thymadine from one of our chemical hoods. This resulted in CSU being able to begin using the hood facility after four years of not being able to use it.”
“The transformation of novel ideas to commercial products is the hallmark of CBI, and we believe DeconGel™ will play a critical role in the management of radiological and nuclear contamination on a global scale,” says Roberto Mandanas, General Manager of DeconGel™. “We plan to enter into strategic alliance with major industry partners in key world markets in the coming months.”
DeconGel™ was initially funded by the Hawaii Technology Development Venture (HTDV) under its contract with the Office of Naval Research (ONR). Additional R&D funding was secured through the USAF Force Protection Battlelab, HTDV, and the National Defense Center of Excellence for Research in Ocean Sciences (CEROS) under its contract with the Defense Advanced Research Projects Agency (DARPA).
For information regarding DeconGel™, go to www.decongel.com, or contact Roberto Mandanas at rmandanas@cellularbioengineering.com.
About CBI
CBI invents, develops, and acquires disruptive technologies to transform novel ideas and innovations to commercial products. The Company has an Intellectual Property portfolio of over 25 patents and patent applications, and four operating divisions including:
- DeconGel™ is a commercialized product with superior efficacy for the containment and decontamination of radioactive and nuclear spills, and with additional applications in industrial cleaning and environmental management.
- Eyegenix™ is a bio-integrating artificial cornea. It is in pilot human clinical trials, and holds the promise of returning sight to 10 million people worldwide who are blind from corneal disease.
- PixiTag™ is a nanoporous silica microtag which can be used to authenticate valuable assets, from great works of art and luxury goods to pills and capsules to be ingested, protecting consumers from loss and the health risks of counterfeit products.
- E Canary is a bio-sensor comprised of living cardiac cells on a CCD chip which can detect both known and unknown harmful threats in the environment such as chemical contaminants and biologic weapons.
Please go to www.cellularbioengineering.com for further information.
Media Contact:
Linda Jameson
(808) 221-3552
ljameson821@gmail.com
Genie in Bottle: Cellular Bioengineering, Inc.
Biotech Firm Sees Cornea Surgery Success
Five years after setting out to manufacture the delicate tissue that enables the human eye to see clearly, Cellular Bioengineering Inc. has completed 10 successful cornea implants abroad.
The Honolulu biotechnology firm’s patented material for artificial corneas is being manufactured locally and last December was used for eye surgeries in Europe.
Cellular Bioengineering Snags the Nation's Top R&D Honors
Cellular Bioengineering Wins Major R&D Award
Cellular Bioengineering Inc. has received one of R&D magazine's R&D 100 Awards, recognizing the world's best innovations in technology in the past year.
The company won the award for its neural matrix chip that allows for the growth of nerve cells in specific patterns on a microchip.
Founder and CEO Hank Wuh is hoping the R&D award will propel his Honolulu-based company into the big leagues of technology companies and generate worldwide attention from corporate and institutional clients....read more.
A Biotech Firm with its Eyes on the Prize

A Potential Billion Dollar Company
A new Hawaii company hopes to make the blind see.
Cellular Bioengineering Inc., a biotech startup focused on regenerative medicine, has applied for patents on its proprietary bioengineering of replacement parts for aging, diseased or damaged tissues and organs.
The work the company is doing at its nondescript laboratory in Moiliili has the potential to revolutionize the way organs are replaced and create a life-sciences powerhouse in Honolulu.
In many ways, Cellular Bioengineer-ing is a nearly perfect model for those promoting Hawaii's economic diversification. The company could develop its technology anywhere, but chose Hawaii not only because of its proximity to Asian markets but also because half of its employees are kamaaina who received advanced degrees and came home from the Mainland.
"This is a potential billion-dollar annual revenue company," ....read more.
Greater Good Radio Interview
Dr. Hank Wuh has a plan to help millions of blind people to see. Cellular Bioengineering, Inc (CBI) has developed technology to produce corneas to be used in eye transplants. This has been talked about as a multi billion dollar venture with serious social benefit. Dr. Wuh left a promising surgery practice to become a full time inventor and entrepreneur.
Dr. Wuh invented medical devices as a resident at the Stanford University Hospital. He now is an inventor, CEO and investor in the life science field. Hear Dr. Wuh’s unique view of business and how a global mission is the new paradigm.
Some questions asked:
Welcome Hank, can you tell us about the Cellular Bioengineering Inc and what they do?
Does Cellular Bioengineering Inc have a stated business strategy or a “mission statement”?
What’s the story behind Cellular Bioengineering?
What is your role in the company?
Where do you do your science?
Did you ever practice medicine?
How did you become interested in this kind of study?
Congratulations on the award from R&D magazine. The R&D 100 Awards, recognizes the world’s best innovations in technology in the past year. How has the award helped you and your company to further your studies?
How are you able to fund your studies?
What are some of the interesting projects you are working on now?
How do you manage your time?
What do you do to support the community?
What was your experience with venture capitalists?
What do entrepreneurs need to do to raise venture capital?